<DOC>
	<DOC>NCT00111995</DOC>
	<brief_summary>This study is designed to evaluate the hemoglobin response to Aranesp® (darbepoetin alfa) in black subjects (African-Americans) with chronic renal failure (CRF) receiving hemodialysis and to examine the safety profile.</brief_summary>
	<brief_title>Evaluating Aranesp® for the Treatment of Anemia in African-American Subjects With Chronic Renal Failure (CRF) Receiving Hemodialysis</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Diagnosis of CRF and 3 times weekly prescribed hemodialysis treatments for at least 8 weeks before signing informed consent No planned change in dialysis modality or schedule Black (as indicated on the Chronic Medical Evidence Disease Report, CMMS Form 2728) Hemoglobin 9.5 to 12.5 g/dL on 2 consecutive occasions during the screening period (1 week + 2 days apart) and baseline hemoglobin level of 9.5 12.5 g/dL (defined as the mean of all measurements taken during the screening and baseline periods) Transferrin saturation greater than or equal to 20% but less than or equal to 50% Stable rHuEPO therapy given 3 times per week by intravenous (IV) route of administration for 6 weeks before randomization (stable is defined as less than or equal to 25% change in prescribed dose over 6 weeks, same route of administration, and no more than 1 missed or withheld dose during each of the two 3week periods before randomization) Scheduled for a livingrelated or living nonrelated donor transplant rHuEPO dose greater than 40,000 units weekly Uncontrolled hypertension (postdialysis diastolic blood pressure greater than 105 mmHg and/or systolic blood pressure greater than 180 mmHg on more than 1 occasion as noted in the collected blood pressure measurements during the screening/baseline period) Congestive heart failure (New York Heart Association [NYHA] Class III or IV) Major surgery (excluding vascular access surgery) within 8 weeks before signing informed consent and during screening/baseline Clinical evidence of active inflammatory disease requiring cyclophosphamide, azathioprine, prednisone or other immunosuppressive therapy within 8 weeks before signing the informed consent and during screening/baseline Currently (at the signing of the informed consent) receiving antibiotics for a systemic infection and during screening/baseline Known positivity for HIV antibody or hepatitis B surface antigen Grand mal seizures within the last year Clinical evidence of current malignancy (other than nonmelanomatous skin malignancy), and/or receiving chemotherapy, and/or radiation therapy for malignancies within 8 weeks of signing the informed consent and during screening/baseline Active systemic hematologic disease (e.g., sickle cell anemia, myelodysplastic syndromes, hematological malignancy, myeloma, hemolytic anemia) within 8 weeks of signing the informed consent and during screening/baseline Clinical evidence of severe hyperparathyroidism (parathyroid hormone [PTH] level greater than 1500 pg/mL or biopsyproven bone marrow fibrosis) at last measurement ALT or AST greater than 2x the upper limit of the normal range Red blood cell transfusions within 8 weeks before signing the informed consent and during screening/baseline Known hypersensitivity to human serum albumin (HSA)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>Chronic Renal Failure (CRF)</keyword>
	<keyword>Anemia</keyword>
</DOC>